FNP-223
Phase 2Small molecule
FNP-223 is one of 29 small molecule programs targeting Progressive Supranuclear Palsy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Progressive Supranuclear Palsy
#DrugCompanyPhaseTrials
1Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ambien
PPurdue Pharma LP
Approved
Rilutek
AAzurity Pharmaceuticals
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Exelon
NovartisPhase 3
Azilect
TevaPhase 3
Depakote
AbbViePhase 2
Aricept
EisaiPhase 2
Lithobid
SSolvay Pharmaceuticals
Phase 2
AMX0035
AAmylyx Pharmaceuticals Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FNP-223. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFerrer Internacional S.A.